




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07D 401/04, 401/12, 213/74, A61K 31/44		A1	(11) International Publication Number: WO 98/35956
			(43) International Publication Date: 20 August 1998 (20.08.98)
(21) International Application Number: PCT/GB98/00405		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 9 February 1998 (09.02.98)		Published With international search report.	
(30) Priority Data: 9702946.6 13 February 1997 (13.02.97) GB 9715734.1 26 July 1997 (26.07.97) GB 9719237.1 11 September 1997 (11.09.97) GB			
(71) Applicant (for all designated States except US): ZENECA LIMITED (GB/GB); 15 Stanhope Gate, London W1Y 6LN (GB).			
(72) Inventor; and (75) Inventor/Applicant (for US only): BROWN, George, Robert (GB/GB); Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).			
(74) Agent: BROWN, Andrew, Stephen; ZENECA Pharmaceuticals, Intellectual Property Dept., Mersey, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).			

(54) Title: HETEROCYCLIC COMPOUNDS USEFUL AS OXIDO-SQUALENE CYCLASE INHIBITORS



(I)

(57) Abstract

This invention concerns heterocyclic derivatives of formula (I) which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	CN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KR	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CJ	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

HETEROCYCLIC COMPOUNDS USEFUL AS OXIDO-SQUALENE CYCLASE INHIBITORS

This invention concerns heterocyclic derivatives which are useful in inhibiting oxido-squalene cyclase, processes for their preparation and pharmaceutical compositions containing them. The present invention is also concerned with heterocyclic derivatives capable of inhibiting cholesterol biosynthesis and hence in lowering cholesterol levels in blood plasma. The present invention also relates to methods of using such heterocyclic derivatives in diseases and medical conditions such as hypercholesterolemia and atherosclerosis.

10 There is evidence that high serum cholesterol levels are an important risk factor in coronary heart disease and associated diseases such as atherosclerosis and ischaemic heart disease. As a result there has been a great deal of interest in finding ways of lowering cholesterol levels in blood plasma. Although it has been possible to obtain some reduction by means of diet only modest reductions in cholesterol levels in blood plasma have been
15 obtained. Consequently, there is a need for therapeutic approaches to reducing cholesterol levels.

Several different classes of compounds have been reported to possess the ability to lower cholesterol levels in blood plasma. For example agents which inhibit the enzyme 3-hydroxy-3-methyl glutaryl CoA (HMGCoA) reductase, which is essential for the
20 production of cholesterol, have been reported to reduce levels of cholesterol in blood plasma (serum cholesterol). Illustrative of this class of compounds is the HMGCoA reductase inhibitor known as lovastatin which is disclosed in US Patent No 4,231,938. Other agents which are reported to lower serum cholesterol include those which act by complexing with bile acids in the intestinal system. Such agents act by sequestering bile
25 acids within the intestinal tract resulting in a lowering of the levels of bile acid circulating in the enterohepatic system. This in turn promotes replacement of bile acids, which are synthesised in the liver from cholesterol. This results in an upregulation of the hepatic LDL cholesterol receptor and in a consequential lowering of circulating blood cholesterol levels.

The biosynthesis of cholesterol is a complex process which will be considered here as three principal stages, namely 1) the conversion of acetic acid to mevalonic acid 2) the conversion of mevalonic acid to squalene and 3) the conversion of squalene to cholesterol. In the last stage, squalene is first converted into 2,3-oxido-squalene and then to lanosterol. 5 Lanosterol is then converted to cholesterol through a number of enzymatic steps.

The conversion of 2,3-oxido-squalene to lanosterol is a key step in the biosynthesis of cholesterol. This conversion is catalysed by the enzyme oxido-squalene cyclase. It follows that inhibition of this enzyme decreases the amount of lanosterol available for conversion to cholesterol. Consequently, inhibition of oxido-squalene cyclase should 10 interrupt cholesterol biosynthesis and give rise to a lowering of cholesterol levels in blood plasma.

The present invention is based on the discovery that certain heterocyclic derivatives are inhibitors of oxido-squalene cyclase and are hence useful in treating diseases and medical conditions in which inhibition of oxido-squalene cyclase is desirable.

15 According to the present invention there is provided a compound of formula I (set out hereinafter together with the other formulae referred to herein in a separate sheet following the Examples), or a pharmaceutically-acceptable acceptable salt thereof, wherein:

R is selected from halogeno, cyano, nitro, carboxy, (1-6C)alkyl, (1-6C)alkoxy, (1- 20 6C)alkanoyl, (1-6C)alkoxycarbonyl and halogeno(1-6C)alkyl;

R₁ is selected from hydrogen, amino, halogeno, cyano, nitro, carboxy, (1-6C) alkyl, (1-6C)alkoxy, (1-6C)alkanoyl, (1-6C)alkoxycarbonyl, halogeno(1-6C)alkyl, N-(1- 6C)alkylamino, N,N-di-[(1-6C)alkyl]amino, (1-6C)alkylthio, (1-6C)alkylsulphinyl and (1- 6C)alkylsulphonyl;

25 m is 1 or 2;

A is selected from a direct bond and (1-4C)alkylene;

T₁ is selected from N and CR₂, wherein R₂ may be hydrogen, (1-4C)alkyl, (2- 4C)alkenyl or (2-4C)alkynyl (preferably R₂ is hydrogen);

T₂ is selected from N and CH;

T_3 is selected from N and CR_2 , wherein R_2 is as defined above; provided that when T_2 is CH then T_3 is not CR_2 and when T_1 is CR_2 then T_3 is not CR_2 ;

wherein the heterocyclic ring containing T_1 and the heterocyclic ring containing T_2 may, independently, be optionally substituted by one or more substituents selected from (1-6C)alkyl, (1-6C)alkoxy, phenyl(1-4C)alkyl, halogeno and (1-6C)alkoxycarbonyl;

Q is selected from phenyl, naphthyl, phenyl(1-6C)alkyl, phenyl(2-6C)alkenyl and a heteroaryl moiety containing up to 3 heteroatoms selected from nitrogen, oxygen and sulphur;

and wherein Q may be unsubstituted or may bear one or more substituents selected from
10 halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-4C)alkyl, (1-4C)alkylenedioxy, (1-6C)alkylamino, N,N-di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, di-N[(1-6C)alkyl]carbamoyl, (1-6C)alkanoylamino, (1-6C)alkoxycarbonyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,
15 halogeno(1-6C)alkyl, (1-6C)alkanoyl and a heteroaryl group comprising a 5- or 6-membered monocyclic heteroaryl ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur.

The compounds of the present invention are oxido-squalene cyclase inhibitors and hence possess the property of inhibiting cholesterol biosynthesis. There is provided as a
20 feature of the invention a compound of formula I (as hereinbefore defined), or a pharmaceutically-acceptable salt thereof, for use in medical therapy. Also provided is the use of a compound of formula I (as hereinbefore defined), or a pharmaceutically-acceptable salt thereof, for the manufacture of a medicament for treating diseases or medical conditions in which inhibition of oxido-squalene cyclase is desirable. There is
25 also provided the use of a compound of formula I (as hereinbefore defined), or a pharmaceutically-acceptable acceptable salt thereof, for the manufacture of a medicament for inhibiting cholesterol biosynthesis. The compounds of the present invention will be useful in treating diseases or medical conditions in which an inhibition of oxido-squalene cyclase is desirable, for example those in which a lowering of the level of cholesterol in
30 blood plasma is desirable. In particular, the compounds of the present invention will be

useful in treating hypercholesterolemia and/or ischaemic diseases associated with atheromatous vascular degeneration such as atherosclerosis.

Thus the present invention also provides the use of a compound of formula I (as hereinbefore defined), or a pharmaceutically-acceptable salt thereof, for the manufacture of
5 a medicament for treating diseases or medical conditions in which a lowering of the level of cholesterol in blood plasma is desirable (such as hypercholesterolemia and atherosclerosis).

Thus according to a further feature of the present invention there is provided a
10 method of inhibiting oxido-squalene cyclase in a warm-blooded animal (such as man) requiring such treatment, which method comprises administering to said animal an effective amount of a compound of formula I (as hereinbefore defined), or a pharmaceutically-acceptable salt thereof. In particular, the present invention provides a method of inhibiting cholesterol biosynthesis, and more particularly to a method of treating
15 hypercholesterolemia and atheromatous vascular degeneration (such as atherosclerosis).

In particular, the compounds of the present invention are potentially useful in inhibiting cholesterol biosynthesis in man and hence in treating the above-mentioned medical conditions in man.

It will be understood that when a compound of formula I contains a chiral centre, it
20 may exist in, and be isolated in, an optically active or racemic form. The invention includes any optically active or racemic form of a compound of formula I which possesses the beneficial pharmacological effect of inhibiting oxido-squalene cyclase. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by, resolution of a racemic form, by synthesis from
25 optically active starting materials or by asymmetric synthesis. It will be appreciated that certain compounds of formula I may exist as geometrical isomers. The invention includes any geometrical isomer of a compound of formula I which possesses the beneficial pharmacological effect of inhibiting oxido-squalene cyclase.

It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It is to be understood that the present invention encompasses all such solvated forms which possess the property of inhibiting oxido-squalene cyclase.

5 It is also to be understood that generic terms such as "alkyl" include both the straight chain and branched chain groups such as butyl and tert-butyl. However, when a specific term such as "butyl" is used, it is specific for the straight chain or "normal" butyl group, branched chain isomers such as "tert-butyl" being referred to specifically when intended.

10

Particular values for R include, for example,

for halogeno; chloro, bromo, iodo or fluoro, particular values are chloro, bromo and iodo;

for alkyl; (1-4C)alkyl, such as methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl or tert-butyl;

15

for alkoxy; methoxy, ethoxy, propoxy, iso-propoxy, butoxy, pentoxy or 3-methylbutoxy;

for alkoxycarbonyl; (1-4C)alkoxycarbonyl, such as, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, iso-propoxycarbonyl, butoxycarbonyl or tert-butoxycarbonyl;

20

for halogenoalkyl halogeno(1-4C)alkyl such as halogenoalkyl containing one, two or three halo groups selected from fluoro, chloro, bromo and iodo and an alkyl group selected from methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl and sec-butyl, thus particular values will include trifluoromethyl, difluoromethyl and fluoromethyl;

25

for alkanoyl; formyl, acetyl, propionyl and butynyl;

Particular values for R₁ include, for example,

30 for halogeno; chloro, bromo or iodo;

	for alkyl;	(1-4C)alkyl, such as methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl or tert-butyl;
	for alkoxy;	methoxy, ethoxy, propoxy, iso-propoxy, butoxy, pentoxy or 3-methylbutoxy;
5	for alkoxycarbonyl;	(1-4C)alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl; propoxycarbonyl, iso-propoxycarbonyl, butoxycarbonyl or tert-butoxycarbonyl;
	for halogenoalkyl;	halogeno(1-4C)alkyl such as halogenoalkyl containing one, two or three halo groups selected from fluoro, chloro, bromo and iodo and an alkyl group selected from methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl and sec-butyl, thus particular values will include trifluoromethyl, difluoromethyl and fluoromethyl;
10		
	for N-alkylamino;	N-(1-4C)alkylamino, such as, N-methylamino, N-ethylamino, N-propylamino or N-butylamino;
15	for N,N-di-[alkyl]amino;	N,N-di-[(1-4C)alkyl]amino, such as N,N-dimethylamino, N,N-diethylamino, N-methyl-N-ethylamino, N-methyl-N-propylamino or N,N-dipropylamino;
	for alkylthio;	methylthio, ethylthio, propylthio, iso-propylthio or butylthio;
20	for alkylsulphinyl;	methylsulphinyl, ethylsulphinyl, propylsulphinyl, iso-propylsulphinyl or butylsulphinyl;
	for alkylsulphonyl;	methylsulphonyl, ethylsulphonyl, propylsulphonyl, iso-propylsulphonyl or butylsulphonyl;
25	for alkanoyl;	formyl, acetyl, propionyl and butyryl;

Particular values for optional substituents on the heterocyclic rings containing T₁ and T₂ include, for example,

30	for alkyl;	(1-4C)alkyl such as methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl or tert-butyl;
----	------------	--

- | | |
|---------------------|---|
| for alkoxy; | (1-4C)alkoxy such as methoxy, ethoxy, propoxy, isopropoxy or butoxy; |
| for phenylalkyl; | phenyl (1-2C)alkyl such as benzyl, 2-phenylethyl or 1-phenylethyl |
| 5 for halogeno; | fluoro, chloro, bromo or iodo |
| for alkoxycarbonyl; | methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl or butyoxycarbonyl; |

Particular values for optional substituents which may be present on Q include, for example,

- | | |
|------------------------------|---|
| 10 for alkyl; | (1-4C)alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl; |
| for cycloalkyl | cyclopropyl, cyclobutyl or cyclopentyl; |
| for cycloalkylalkyl | (3-6C)cycloalkyl(1-2C)alkyl such as cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl or cyclopentylmethyl; |
| 15 for alkenyl; | (2-4C)alkenyl, such as allyl, prop-1-enyl, 2-methyl-2-propenyl or 2-butenyl; |
| for alkynyl; | (2-4C)alkynyl, such as prop-2-ynyl or but-2-ynyl; |
| for alkoxy; | (1-6C)alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, pentoxy or 3-methylbutoxy; |
| 20 for alkylamino; | (1-4C)alkylamino, such as methylamino, ethylamino, propylamino or butylamino; |
| for N,N-di-[alkyl]amino; | N,N-di-[(1-4C)alkyl]amino such as N,N-dimethylamino, N,N-diethylamino, N-methyl-N-propylamino or N,N-dipropylamino; |
| 25 for N-alkylcarbamoyl; | N-(1-4C)alkylcarbamoyl such as N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N-butylcarbamoyl or N-tert-butylcarbamoyl or (N-(2-methylpropyl)carbamoyl; |
| for N,N-di-[alkyl]carbamoyl; | N,N-di-[(1-4C)alkyl]carbamoyl, N,N-dimethylcarbamoyl or N,N-diethylcarbamoyl; |

	alkoxycarbonyl;	(1-4C)alkoxycarbamoyl such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, iso-propoxycarbonyl, butoxycarbonyl or tert-butoxycarbonyl;
	for alkylthio;	(1-4C)alkylthio such as methylthio, ethylthio, propylthio, iso-propylthio or butylthio;
5	for alkylsulphinyl;	(1-4C)alkylsulphinyl such as methylsulphinyl, ethylsulphinyl, propylsulphinyl, iso-propylsulphinyl or butylsulphinyl;
	for alkylsulphonyl;	(1-4C)alkylsulphonyl such as methylsulphonyl, ethylsulphonyl, propylsulphonyl, iso-propylsulphonyl or butylsulphonyl;
10	for halogeno;	fluoro, chloro, bromo or iodo;
	for halogenoalkyl;	halogeno(1-4C)alkyl such as halogenoalkyl containing one, two or three halo groups selected from fluoro, chloro, bromo and iodo and an alkyl group selected from methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl and sec-butyl, thus particular values will include trifluoromethyl, difluoromethyl and fluoromethyl;
15	for alkanoylamino;	(1-4C)alkanoylamino such as formamido, acetamido, propionamido, iso-propionamido, butyramido and iso-butyramido;
20	for alkylenedioxy;	methylenedioxy or ethylenedioxy;
	for alkanoyl;	(1-4C)alkanoyl such as formyl, acetyl, propionyl or butyryl;

25 In general, it is preferred, that R_1 is hydrogen and m is 1.

In general, it is preferred that R is selected from halogeno, trifluoromethyl and cyano. More preferably, R is halogeno such as chloro, bromo or fluoro.

In general, it is preferred, for example, that A is a direct bond.

30 In general, the heterocyclic rings containing T_1 and T_2 will be unsubstituted or bear one or two substituents selected from those hereinbefore defined.

In general it is preferred, for example, that Q is phenyl, naphthyl or phenyl(2-6C)alkenyl (such as styryl) or a 5- or 6-membered heteroaryl moiety as herein before defined (such as thienyl). More preferably, Q is phenyl.

In general, Q will be unsubstituted or will bear one, two or three (preferably one or two) substituents selected from those hereinbefore defined.

Particular values for Q when it is a heteroaryl moiety which comprises a 5- or 6-membered heteroaryl moiety which is fused to one or two benzo rings are, for example, benzofuranyl, benzothienyl, quinolyl, isoquinolyl, quinoxaliny, quinazoliny, cinnoliny, indolyl, indazolyl, benzoxazolyl and benzothiazolyl which may be attached through any available position including through any available nitrogen atom.

Particular values for Q, or substituted on Q, when either or both are a heteroaryl which comprises a 5- or 6-membered monocyclic heteroaryl ring are, for example, furyl, thienyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, furazanyl, tetrazolyl and thiadiazolyl which may be attached through any available position including through any available nitrogen atom.

A particular value for Q when it is naphthyl is, for example, 1-naphthyl or 2-naphthyl.

A particular value for Q when it is phenylalkyl is, for example, phenyl(1-2C)alkyl, such as benzyl, 2-phenylethyl or 1-phenylethyl.

A particular value for Q when it is phenylalkenyl, for example, phenyl(2-4C)alkenyl such as styryl, cinnamyl or 3-phenylprop-2-enyl.

Specific values for optional substituents on the heterocyclic ring containing T₁ or the heterocyclic ring containing T₂ include, for example (1-6C)alkyl (such as methyl) and (1-6C)alkoxycarbonyl (such as methoxycarbonyl or ethoxycarbonyl).

Specific values for optional substituents for Q include, for example, halogeno (such as fluoro, chloro, bromo or iodo), (1-6C)alkoxy (such as methoxy or ethoxy), (1-6C)alkyl (such as methyl, iso-propyl or t-butyl), halogeno(1-6C)alkyl (such as trifluoromethyl), N,N-di-[(1-4C)alkyl]amino (such as N,N-dimethylamino), nitro, cyano, and (1-6C)alkanoylamino (such as acetylamino).

Specific values for R_1 include, for example, hydrogen, amino, (1-6C)alkyl (such as methyl) and halogeno (such as chloro or bromo). More preferably R_1 is hydrogen.

Specific values for R include, for example, halogeno, such as bromo or chloro, and halogeno(1-6C)alkyl, such as trifluoromethyl.

5 In a particular embodiment, the heterocyclic rings containing T_1 and T_2 are unsubstituted.

In a particular embodiment there is provided a compound of formula I, or a pharmaceutically-acceptable acceptable salt thereof, wherein

T_1 is selected from CH and N;

10 R is selected from halogeno, cyano, and trifluoromethyl, preferably halogeno;

R_1 is hydrogen, amino, halogeno, cyano, nitro, carboxy, (1-6C)alkanoyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkoxycarbonyl, halogeno(1-6C)alkyl, N-(1-6C)alkylamino, N,N-di-[(1-6C)alkyl]amino, (1-6C)alkylthio, (1-6C)alkylsulphinyl and (1-6C)alkylsulphonyl, preferably hydrogen;

15 m is 1 or 2, preferably 1;

A is a direct bond;

T_2 is selected from CH and N;

T_3 is selected from CH and N; provided that when T_2 is CH then T_3 is not CH and when T_1 is CH then T_3 is not CH;

20 wherein the heterocyclic ring containing T_1 and the heterocyclic ring containing T_2 may, independently, be optionally substituted by one or more substituents selected from (1-6C)alkyl, (1-6C)alkoxy, phenyl(1-4C)alkyl, halogeno and (1-6C)alkoxycarbonyl;

Q is selected from phenyl, naphthyl, and phenyl(2-6C)alkenyl, preferably phenyl;

and wherein Q may be unsubstituted or may bear one or more substituents selected from
25 halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-4C)alkyl, (1-4C)alkylenedioxy, (1-6C)alkylamino, N,N-di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (1-6C)alkanoylamino, (1-6C)alkoxycarbonyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl,
30 halogeno(1-6C)alkyl, (1-6C)alkanoyl and a heteroaryl group comprising a 5- or 6-

membered monocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur, preferably halogeno.

Further particular embodiments of the present invention include the following in which A is a direct bond or methylene, R is selected from halogeno, cyano and trifluoromethyl, R₁ and m are as hereinbefore defined, the rings containing T₁ and T₂ are optionally substituted as hereinbefore defined, and T₁, T₂, T₃ and Q are as defined in any one of the following groups:

- (i) T₁ = CH, T₂ = T₃ = N, Q = phenyl;
- 10 (ii) T₁ = CH, T₂ = T₃ = N, Q = naphthyl;
- (iii) T₁ = CH, T₂ = T₃ = N, Q = phenyl(2-6C)alkenyl (such as styryl);
- (iv) T₁ = CH, T₂ = T₃ = N, Q = 5- or 6-membered heteroaryl such as thienyl;
- (v) T₁ = N, T₂ = CH, T₃ = N, Q = phenyl;
- (vi) T₁ = N, T₂ = CH, T₃ = N, Q = naphthyl;
- 15 (vii) T₁ = N, T₂ = CH, T₃ = N, Q = phenyl(2-6C)alkenyl (such as styryl);
- (viii) T₁ = N, T₂ = CH, T₃ = N, Q = 5- or 6-membered heteroaryl such as thienyl;
- (ix) T₁ = T₂ = T₃ = N, Q = phenyl;
- (x) T₁ = T₂ = T₃ = N, Q = naphthyl;
- (xi) T₁ = T₂ = T₃ = N, Q = phenyl(2-6C)alkenyl (such as styryl); or
- 20 (xii) T₁ = T₂ = T₃ = N, Q = 5- or 6- membered heteroaryl such as thienyl,

and wherein Q is preferably unsubstituted or substituted by one or two substituents independently selected from halogeno (such as bromo, fluoro or chloro), (1-6C)alkyl (such as methyl) and (1-6C)alkoxy (such as methoxy) or is a halogeno(1-6C)alkyl (such as trifluoromethyl).

25 More particular embodiments include those in which A is a direct bond, R is halogeno, R₁ is H, m is 1, the rings containing T₁ and T₂ are unsubstituted, or R₁ is hydrogen or (1-6C)alkyl and m is 1 or 2 (preferably 1), and T₁, T₂, T₃ and Q are as defined in any one of the following groups:

- 30 (i) T₁ = CH, T₂ = T₃ = N, Q = phenyl;

- (ii) $T_1 = \text{CH}$, $T_2 = T_3 = \text{N}$, $Q = \text{naphthyl}$;
 - (iii) $T_1 = \text{CH}$, $T_2 = T_3 = \text{N}$, $Q = \text{phenyl(2-6C)alkenyl}$ (such as styryl);
 - (iv) $T_1 = \text{CH}$, $T_2 = T_3 = \text{N}$, $Q = 5\text{- or }6\text{-membered heteroaryl}$ such as thienyl;
 - (v) $T_1 = \text{N}$, $T_2 = \text{CH}$, $T_3 = \text{N}$, $Q = \text{phenyl}$;
 - 5 (vi) $T_1 = \text{N}$, $T_2 = \text{CH}$, $T_3 = \text{N}$, $Q = \text{naphthyl}$;
 - (vii) $T_1 = \text{N}$, $T_2 = \text{CH}$, $T_3 = \text{N}$, $Q = \text{phenyl(2-6C)alkenyl}$ (such as styryl);
 - (viii) $T_1 = \text{N}$, $T_2 = \text{CH}$, $T_3 = \text{N}$, $Q = 5\text{- or }6\text{-membered heteroaryl}$ such as thienyl;
 - (ix) $T_1 = T_2 = T_3 = \text{N}$, $Q = \text{phenyl}$;
 - (x) $T_1 = T_2 = T_3 = \text{N}$, $Q = \text{naphthyl}$;
 - 10 (xi) $T_1 = T_2 = T_3 = \text{N}$, $Q = \text{phenyl(2-6C)alkenyl}$ (such as styryl); or
 - (xii) $T_1 = T_2 = T_3 = \text{N}$, $Q = 5\text{- or }6\text{-membered heteroaryl}$ such as thienyl,
- and wherein Q is preferably unsubstituted or substituted by one or two substituents independently selected from halogeno (such as bromo, fluoro or chloro), (1-6C)alkyl (such as methyl) and (1-6C)alkoxy (such as methoxy) or is a halogeno(1-6C)alkyl (such as
- 15 trifluoromethyl).

In a further embodiment R is selected from halogen(1-6C)alkyl, nitro, carboxy, (1-6C)alkanoyl and (1-6C)alkoxycarbonyl; and R_1 , m , A , T_1 , T_2 , T_3 and Q are as hereinbefore defined.

In a specific embodiment, T_2 is N , T_1 is CH , T_3 is N or T_2 is N , T_1 is N and T_3 is

20 CH , R is chloro or bromo, R_1 is hydrogen or (1-6C)alkyl, m is 1 or 2 and Q is phenyl optionally substituted by halogeno, (1-6C)alkyl or (1-6C)alkoxy.

Compounds of special interest include those described in the accompanying examples and their pharmaceutically-acceptable acceptable salts and are hence provided as a further feature of the present invention.

25 The compounds of formula I and their pharmaceutically-acceptable acceptable salts may be prepared by processes known to be applicable to the preparation of structurally related compounds. These procedures are illustrated by the following representative processes in which the various groups and radicals such as R_1 , m , T_1 , A , T_2 , T_3 , and Q are as hereinbefore defined (unless stated otherwise), and are provided as a

30 further feature of the present invention. In cases where the compounds contain a group such as an amino, hydroxy, or carboxy group, this group may be protected using a

conventional protecting group which may be removed when desired by conventional means.

(a) When T_3 is N, reacting an acid of formula II, or a reactive derivative thereof, with an amine of formula III.

- 5 A suitable reactive derivative of an acid of formula II is, for example, an acyl halide such as an acyl chloride formed by the reaction of the acid with an inorganic acid chloride such as thionyl chloride. Further suitable reactive derivatives include a mixed anhydride such as an anhydride formed by the reaction of the acid with a chloroformate such as isobutyl chloroformate; an active ester such as an ester formed by the reaction of the acid and
- 10 a phenol such as pentafluorophenol, an ester such as pentafluorophenyl trifluoroacetate or an alcohol such as N-hydroxybenzotriazole or N-hydroxysuccinimide; an acylazide, for example an azide formed by the reaction of the acid and an azide as diphenylphosphoryl azide; an acyl cyanide, for example a cyanide formed by the reaction of an acid and a cyanide such as diethylphosphoryl cyanide; or the product of the reaction of the acid and a
- 15 carbodiimide such as N,N'-dicyclohexylcarbodiimide or N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide.

- The reaction is conveniently carried out in the presence of a suitable base such as, for example, an alkali or alkaline earth metal carbonate, alkoxide, hydroxide or hydride, for example sodium carbonate, potassium carbonate, sodium ethoxide, potassium butoxide,
- 20 sodium hydroxide, potassium hydroxide, sodium hydride or potassium hydride, or an organometallic base such as an alkyl-lithium, for example n-butyl-lithium, or a dialkylamino-lithium, for example lithium di-isopropylamide, or, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine or diazabicyclo[5.4.0]undec-7-ene. The
- 25 reaction is also preferably carried out in a suitable inert solvent or diluent, for example methylene chloride, chloroform, carbon tetrachloride, tetrahydrofuran, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidin-2-one, dimethylsulphoxide or acetone, and at a temperature in the range, for example, -78° to 150°C , conveniently at or near ambient temperature.

- 30 A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for

example a methoxycarbonyl, ethoxycarbonyl or tert-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an

5 alkanoyl or alkoxy carbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a tert-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a

10 benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

15 A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for

20 example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying

25 group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a tert-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

30 (b) When T_2 is N, reacting an amine of formula IV, with a compound of formula Z-SO₂-Q in which Z is a displaceable group.

The reaction will, in general, be conveniently carried out in the presence of a suitable base. Suitable bases are those mentioned in (a) above.

A suitable value for the displaceable group Z is, for example, a halogeno or sulphonyloxy group, for example a fluoro, chloro, bromo, mesyloxy or 4-
5 tolylsulphonyloxy group.

The reaction is conveniently performed in a suitable inert solvent or diluent as defined hereinbefore and at a temperature in the range, for example, 0° to 150°C, conveniently at or near ambient temperature.

(c) When T₁ is N, and wherein A is a direct bond, reacting a compound of formula V
10 with an acid of formula VIII or a reactive derivative thereof.

The reaction will, in general, be carried out in the presence of a suitable base as mentioned in (a) above.

The reaction is conveniently performed in a suitable inert solvent or diluent as defined hereinbefore and at a temperature in the range, for example 0° to 150°C,
15 conveniently at or near ambient temperature.

(d) Reacting a compound of formula VI in which Z is a displaceable group with an amine of formula VII.

The reaction will, in general, be carried out in the presence of a suitable base as mentioned in (a) above.

20 Suitable values for Z are those mentioned in (b) above.

The reaction is conveniently carried out in a suitable inert solvent as mentioned in (a) above and at a temperature in the range, for example 0°C to 150°C, conveniently in the range 15°C to 100°C.

(e) For those compounds of formula I in which R is a halogeno, halogenating the
25 corresponding compound of formula I in which R is hydrogen.

In particular, the halogenation may be carried out using a N-halosuccinimide (eg. N-bromosuccinimide, N-chlorosuccinimide or N-iodosuccinimide). These halogenations may conveniently be carried out at 0 to 100°C in a polar solvent such as tetrahydrofuran, methanol, dimethylformamide or acetonitrile.

Intermediate compounds of formula I where R is hydrogen also have activity against the enzyme oxido-squalene cyclase and may also be used in treating or preventing diseases and conditions mentioned above.

As mentioned above, it will be appreciated that in some of the reactions mentioned
5 herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Thus, if reactants include groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned
herein. Suitable protecting groups are mentioned under (a) above. The protecting groups
10 may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

It will also be appreciated that certain of the various optional substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or
15 immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular
20 examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acylhalide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group.
25 Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

When a pharmaceutically-acceptable salt of a compound of the formula I is
30 required, it may be obtained, for example, by reaction of said compound with the appropriate acid (which affords a physiologically acceptable anion), or with the appropriate

base (which affords a physiologically acceptable cation), or by any other conventional salt formation procedure.

When an optically active form of a compound of the formula I is required, it may be obtained, for example, by carrying out one of the aforesaid procedures using an
5 optically active starting material or by resolution of a racemic form of said compound using a conventional procedure.

The beneficial pharmacological properties of the compounds of the present invention may be demonstrated using one or more of the following techniques.

10 (a) In vitro test to measure inhibition of oxido-squalene cyclase

This test measures the inhibition of microsomal oxido-squalene cyclase *in vitro* by compounds at set concentrations in the incubation medium.

Microsomes are prepared from rat liver according to methods known in the art, for example, the method described in published European Patent Application No 324,421 and
15 stored in liquid nitrogen prior to assay. Assay vials are kept at 37°C throughout the incubation. The microsomes typically contain 15-20mg of protein per ml of microsomes. For the assay, 1ml of microsomes are diluted by the addition of 722µl of 50mM phosphate buffer pH 7.4.

Phosphate buffered Tween® 80 (polyoxyethylene sorbitan monolaurate) is
20 prepared by adding 0.1g Tween® 80 to 100ml of 50mM phosphate buffer.

A stock solution of oxido-squalene is made up as a solution in ethanol (0.65mg. ml.⁻¹). 18µl of radio-labelled oxido-squalene (1µCi.ml⁻¹) is evaporated to dryness under a stream of nitrogen and redissolved in 1ml of ethanol and 1ml of the stock solution of oxido-squalene is added.

25 The test compound is dissolved in dimethyl sulphoxide to give a 10⁻¹M stock solution. Dilutions are made from the stock to give 10⁻⁵M, 10⁻⁶M etc.

Phosphate buffered Tween® 80 (28µl) is placed in 5ml disposable plastic vials and 4µl of the solution of the test compound is added and mixed well. An aliquot of the oxido-squalene mix (15µl) is added and the vials pre-incubated for 10 minutes at 37°C. A
30 portion of the microsomes (14.6µl) are then added and incubated for a further 1 hour. The reaction is stopped by the addition of 315µl of a mixture of 16% KOH in 20% ethanol.

The samples are then placed in a water bath at 80°C for 2 hours to saponify. At the end of this process water (630µl) is added followed by hexane (5ml). The samples are tumble mixed for 5 minutes and then centrifuged. The hexane phase is removed and evaporated under nitrogen. The samples are then reconstituted in 300µl of a 80:20 mixture of acetonitrile:iso-propyl alcohol. The samples are then chromatographed using a Hichrom® 30DsS1 column with an isocratic elution using a 95:5 mixture of acetonitrile:isopropyl alcohol and a flow rate of 1ml.min⁻¹. The output from the UV detector is connected to a radio-chemical detector to visualise radiolabelled sterols. Reaction rate is measured as the conversion of oxido-squalene to lanosterol, and the effects of test compounds are expressed as an inhibition of this process.

By way of example, the compound described in Example 1 gave about 79% inhibition of rat microsomal oxido-squalene cyclase at a concentration of 0.01µM.

(b) In vivo test to measure inhibition of oxido-squalene cyclase

The ability of a compound to inhibit oxido-squalene cyclase and/or inhibit cholesterol biosynthesis may be assessed by a routine laboratory procedure carried out in the rat. The test involves administration of the compound to rats on a reversed lighting regimen. Female rats (35-55g) are housed in reverse lighting conditions (red light from 0200h - 1400h) for a period of about 2 weeks prior to test. Animals are allowed free access to chow and drinking water throughout this period. At test, animals should weigh 100 - 140g. The rats are dosed orally with the compound (typically 10-50mg/kg) formulated in a polyethylene glycol/hydroxypropylmethyl cellulose mix. After 1 hour the rats are given triturated sodium mevalonate (15µCi.kg⁻¹) intraperitoneally. Two hours after administration of the compound the rats are terminated and a piece of liver removed and weighed. The tissue is saponified at 80°C for 2 hours in an ethanolic/potassium hydroxide solution (80% w/v aqueous KOH diluted 1:10 with ethanol). Water (2ml) is added and the mixture extracted with iso-hexane (2 x 5ml). The organic extracts are combined, evaporated to dryness under a stream of nitrogen and the residue is dissolved in a mixture of acetonitrile/iso-propanol (300µl). An aliquot (200µl) of this solution is loaded onto a HPLC column to separate the sterols. The radio-label content of each fraction is assessed using a radio chemical flow detector. Inhibitors of oxido-squalene cyclase are classed as

those compounds which cause a build up of substrate and a concomitant disappearance of cholesterol and its precursors.

By way of example, the compound described in Example 1 below gave about 79% inhibition of rat cholesterol biosynthesis when dosed at 2mg.kg⁻¹.

5 No overt toxicity was detected when compounds of the formula I were administered at several multiples of their minimum inhibitory dose or concentration.

When used in the treatment of diseases and medical conditions such as those mentioned above it is envisaged that a compound of formula I, or a pharmaceutically-acceptable acceptable salt thereof, will be administered orally, intravenously, or by some
10 other medically acceptable route so that a dose in the general range of, for example, 0.01 to 10mg per kg body weight is received. However it will be understood that the precise dose administered will necessarily vary according to the nature and severity of the disease, the age and sex of the patient being treated and the route of administration.

In general, the compounds of formula I, or a pharmaceutically-acceptable salt
15 thereof, will usually be administered in the form of a pharmaceutical composition, that is together with a pharmaceutically-acceptable acceptable diluent or carrier, and such a composition is provided as a further feature of the present invention.

A pharmaceutical composition of the present invention may be in a variety of dosage forms. For example, it may be in the form of tablets, capsules, solutions or
20 suspensions for oral administration; in the form of suppository for rectal administration; in the form of a sterile solution or suspension for parenteral administration such as by intravenous or intramuscular injection.

A composition may be obtained by conventional procedures using pharmaceutically-acceptable acceptable diluents and carriers well known in the art. Tablets
25 and capsules for oral administration may conveniently be formed with a coating, such as an enteric coating (for example, one based on cellulose acetate phthalate), to minimise dissolution of the active ingredient of formula I, or a pharmaceutically-acceptable salt thereof, in the stomach or to mask unpleasant taste.

The compounds of the present invention may, if desired, be administered together
30 with (or sequentially to) one or more other pharmacological agents known to be useful in the treatment of cardiovascular disease, for example, together with agents such as HMG-

CoA reductase inhibitors, bile acid sequestrants, other hypocholesterolaemic agents such as fibrates, for example gemfibrozil, and drugs for the treatment of coronary heart disease.

Compounds which have the same general formula as formula I but in which R is hydrogen are described in published PCT patent application No. WO 96/10022. This reference also describes the preparation of intermediates useful in the preparation of compounds of formula I in general and in particular to some of the compounds described below.

The invention will now be illustrated by the following non-limiting Examples in which, unless otherwise stated:-

- 10 (i) evaporations were carried out by rotary evaporation *in vacuo*;
- (ii) operations were carried out at room temperature, that is in the range 18-26°C;
- (iii) flash column chromatography or medium pressure liquid chromatography (MPLC) was performed on silica gel (Merck Kieselgel Art.9385, obtained from E Merck, Darmstadt, Germany);
- 15 (iv) yields are given for illustration only and are not necessarily the maximum attainable by diligent process development;
- (v) proton NMR spectra were normally determined at 200 MHz using tetramethylsilane (TMS) as an internal standard, and are expressed as chemical shifts (delta values) obtained in DMSO-d₆ (unless stated otherwise) in parts per million relative to TMS using
- 20 conventional abbreviations for designation of major peaks: s, singlet; m, multiplet; t, triplet; br, broad; d, doublet; and
- (vi) all end-products were characterised by microanalysis, NMR and/or mass spectroscopy.

Example 1

25

N-Chlorosuccinimide (150mg) was added to a stirred suspension of 1-(4-bromophenylsulphonyl)-4-[1-(4-pyridyl)piperidin-4-ylcarbonyl]piperazine (493mg) in acetonitrile (200ml) at 25°C. The mixture was stirred for 18 hours. The acetonitrile was removed by evaporation. Water (20ml) was added to the mixture and the aqueous phase

30 was extracted with dichloromethane (2 x 25ml). The organic extracts were combined, dried and evaporated. The residue was purified by chromatography on silica gel using a

mixture of dichloromethane:methanol: 0.88 ammonia (96:3:1) as eluent to give 1-(4-bromophenylsulphonyl)-4-[1-(1-(3-chloro-4-pyridyl)piperidin-4-ylcarbonyl)]piperazine as a colourless foam (381 mg): ¹HNMR (CDCl₃): 1.70-1.80(m, 2H), 1.92-2.08(m, 2H), 2.53-2.62(m, 1H), 2.71-2.81(m, 2H), 3.02(br, 4H), 3.57-3.80(m, 6H), 6.78(d, 1H), 7.61(d, 2H),
5 7.70(d, 2H), 8.25(d, 1H), 8.38(s, 1H): MS.EI m/z 527 (M+H).

1-(4-Bromophenylsulphonyl)-4-[1-(4-pyridyl)piperidin-4-ylcarbonyl]piperazine, used as starting material was prepared as described in published International Patent Application No. WO96/10022 (see, in particular Example 41, compound no. 1).

10 Example 2

Using an analogous procedure to that described in Example 1 (using N-bromo or N-chlorosuccimide as halogenating agent) the following compounds (1-9) were prepared.




Table 1

Compd no	R	T _i	T ₃	R _i	W	m.p. (°C)	¹ H NMR (CDCl ₃)
1	Br	CH	N	H	4-Br	137	1.7-1.82 (m, 2H), 2.0 (m, 2H), 2.58 (m, 1H), 2.75 (d, 2H), 3.02 (bs, 4H), 3.68 (m, 6H), 6.8 (d, 1H), 7.62 (d, 2H), 7.7 (d, 2H), 8.32 (d, 1H), 8.58 (s, 1H)
2	Cl	CH	N	CH ₃	4-Br	139	1.56-1.78 (m, 2H), 1.89 (m, 2H), 2.46 (s, 3H), 2.68 (m, 1H), 3.02 (m, 6H), 3.68 (m, 4H), 4.41 (d, 2H), 7.41 (d, 2H), 7.52 (d, 2H), 8.2 (s, 1H)
3	Cl	N	CH	H	4-Br	156	1.75 (m, 2H), 2.0 (m, 2H), 2.58 (m, 1H), 2.76 (m, 2H), 3.04 (bs, 4H), 3.69 (m, 6H), 6.79 (d, 1H), 7.61 (d, 2H), 7.70 (d, 2H), 8.28 (d, 1H), 8.39 (s, 1H)
4	Br	CH	N	CH ₃	4-Br	105	1.70 (m, 2H), 1.90 (m, 2H), 2.48 (s, 3H), 2.65 (m, 1H), 2.93 (m, 2H), 3.10 (m, 4H), 3.70 (m, 4H), 4.37 (d, 2H), 7.59 (d, 2H), 7.70 (d, 2H), 8.28 (s, 1H)
5	Cl	CH	N	H	3-F	192	1.75 (m, 2H), 2.0 (m, 2H), 2.60 (m, 1H), 2.78 (m, 2H), 3.05 (bs, 4h), 3.68 (m, 6H), 6.79 (d, 1H), 7.35 (m, 1H), 7.47 (m, 1H), 7.55 (m, 2H), 8.28 (d, 1H), 8.39 (s, 1H)

Compd no	R	T ₁	T ₃	R ₁	R ₂	m.p. (°C)	NMR (CDCl ₃)
6	Cl	CH	N	H	4-F	foam	1.75 (m, 2H), 2.0 (m, 2H), 2.60 (m, 1H), 2.78 (m, 2H), 3.04 (bs, 4H), 3.68 (m, 6H), 6.79 (d, 1H), 7.27 (m, 2H), 7.78 (m, 2H), 8.28 (d, 1H), 8.39 (s, 1H)
7	Cl	CH	N	H	4-OMe	foam	1.75 (m, 2H), 2.0 (m, 2H), 2.57 (m, 1H), 2.76 (td, 2H), 3.04 (bs, 4H), 3.66 (m, 6H), 3.83 (s, 3H), 6.78 (d, 1H), 7.02 (d, 2H), 7.68 (d, 2H), 8.26 (d, 1H), 8.39 (s, 1H)
8	Cl	CH	N	H	4-CH ₃	164	1.75 (m, 2H), 2.0 (m, 2H), 2.42 (s, 3H), 2.57 (m, 1H), 2.76 (td, 2H), 3.01 (m, 4H), 3.69 (m, 6H), 6.79 (d, 1H), 7.36 (d, 2H), 7.61 (d, 2H), 8.26 (d, 1H), 8.39 (s, 1H)
9	Cl	N	N	H	4-Br	193	3.04 (t, 4H), 3.16 (t, 4H), 3.41 (m, 8H), 6.78 (d, 1H), 7.61 (d, 2H), 7.68 (d, 2H), 8.32 (d, 1H), 8.42 (s, 1H)

The starting materials were prepared in a similar manner to the preparation of 1-(4-bromophenylsulphonyl)-4-[1-(4-pyridyl)piperidin-4-yl] carbonyl]piperazine referred to in Example 1. As mentioned in Example 1, the starting materials may be prepared using analogous processes to those described in published International Patent Application No. WO 96/10022 and in particular Example 41.

Example 3

N-Chlorosuccinimide (3.06 g) was added to a stirred suspension of 1-(4-bromophenylsulphonyl)-4-[1-(4-pyridyl)piperazin-4-ylcarbonyl]piperazine (10.1 g) in acetonitrile (350 ml) at 20°C. The mixture was stirred for 48 hours and the acetonitrile evaporated. Water (200 ml) was added to the mixture and the aqueous phase was extracted with dichloromethane (3×200 ml). The organic extracts were combined, dried and evaporated, and the residue purified by column chromatography on silica gel, eluting with dichloromethane:methanol (97:3) to give a foam on evaporation. Trituration with diethyl ether (200 ml) gave 1-(4-bromophenylsulphonyl)-4-[1-(3-chloro-4-pyridyl)piperazin-4-ylcarbonyl] piperazine as a cream-coloured solid (7.82 g): mp 194-195°C: ¹HNMR (CDCl₃); 3.04 (t, 4H), 3.18 (t, 4H), 3.42 (m, 8H), 6.78 (d, 1H), 7.91 (d, 2H), 7.70 (d, 2H), 8.34 (d, 2H), 8.42 (s, 1H); EI-MS m/z 528 (M+H).

The starting material was prepared as follows:

4-Pyridylpiperazine (18.5 g) was added to a stirred suspension of 4-nitrophenyl(4-t-butoxycarbonyl)piperazine-1-carboxylate (40 g) in DMF (450 ml). The reaction mixture was heated at 120°C for 22 hours. The DMF was removed by evaporation and the residue triturated with water (500 ml) and dichloromethane (500 ml) added. The organic phase was washed with sodium hydroxide solution (6× 250 ml) and saturated brine (2× 250 ml), dried and evaporated. The residue was purified by chromatography on silica gel using a mixture of dichloromethane:methanol (97:3) as eluant to give a solid.

A solution of the above crude solid (20 g) in dichloromethane (120 ml) was treated at 5°C with a solution of trifluoroacetic acid (80 ml) in dichloromethane (40 ml). The reaction mixture was stirred for 2 hours. The solvent and excess trifluoroacetic acid were removed *in vacuo*. The residue was treated with saturated brine solution (200 ml) and basified to pH 12 with 40% sodium hydroxide solution. The aqueous phase was extracted with dichloromethane (3 × 200 ml). The combined organic phases were washed with saturated brine solution, dried and evaporated to give, as an amber oil, 1-(4-

pyridyl)piperazin-4-ylcarbonyl-1-piperazine (10.2 g) : ¹HNMR (CDCl₃): 2.90 (t, 4H), 3.32 (t, 4H), 3.38 (m, 8H), 6.65 (d, 2H), 8.30 (d, 2H) ; m/z 276 (M+H).

A solution of 4-bromophenylsulphonyl chloride (6.85 g) in dichloromethane (100 ml) was added dropwise to a stirred solution of the above piperazine derivative (7.34 g) in dichloromethane (100 ml) containing triethylamine (7 ml) over 10 minutes and the mixture stirred for 2 hours at 20°C

The organic phase was washed with water, dried and evaporated. The residue was purified by chromatography on silica gel, eluting with a mixture of dichloromethane:methanol (95:5) to give, as a yellow solid, 1-(4-bromophenylsulphonyl)-4-[1-(4-pyridyl)piperazin-4-ylcarbonyl]piperazine (7.1 g) : ¹HNMR (CDCl₃) : 3.04 (t, 4H), 3.32 (m, 12H), 6.62 (d, 2H), 7.58 (d, 2H), 7.68 (d, 2H), (d, 2H) : m/z 494 (M+H).

Example 4

In a similar manner to Example 3 were prepared the compounds described in Table 1




Table 1

Ex.	W	mp (°C)	¹ HNMR (CDCl ₃)
A	4-CF ₃	159-160	3.06 (t, 4H), 3.15 (t, 4H), 3.40 (t, 8H), 6.78 (d, 1H), 7.82 (d, 2H), 7.90 (d, 2H), 8.33 (d, 1H), 8.42 (s, 1H)
B	4-F	143-144	3.04 (t, 4H), 3.15 (t, 4H), 3.41 (t, 4H), 6.78 (d, 1H), 7.21 (d, 2H), 7.78 (d, 2H), 8.33 (d, 1H), 8.42 (s, 1H)
C	4-Cl	162-163	3.04 (t, 4H), 3.16 (t, 4H), 3.40 (m, 8H), 6.79 (d, 1H), 7.52 (d, 2H), 7.75 (d, 2H), 8.32 (d, 1H), 8.42 (s, 1H)

The following starting materials were isolated and characterised in an analogous manner to Example 3.

For A - A sandy-coloured solid, 1-(4-trifluoromethylphenylsulphonyl)-4-[1-(4-pyridyl)piperazin-4-ylcarbonyl]piperazine (6.0g): ^1H NMR (CDCl_3): 3.08(t, 4H), 3.30-3.40(m, 8H), 4.30-4.35(t, 4H), 6.63(d, 2H), 7.82(d, 2H), 7.90(d, 2H), 8.30(d, 2H), EI-MS
5 m/z 484(M+H).

For B - 1-(4-Fluorophenylsulphonyl)-4-[1-(4-pyridyl)piperazin-4-ylcarbonyl]piperazine as a pale yellow solid (9.18g): m.p. 143-144°C: ^1H NMR (CDCl_3): 3.04(t, 4H), 3.15(t, 4H), 3.41(t, 8H), 6.78(d, 1H), 7.21(d, 2H), 7.78(m, 2H), 8.33(d, 1H), 8.42(s, 1H), EI-MS m/z 468(M+H).

10 For C - A sandy-coloured solid, 1-(4-chlorophenylsulphonyl)-4-[1-(4-pyridyl)piperazin-4-ylcarbonyl]piperazine (10.5g) m.p. 184-186°C: ^1H NMR (CDCl_3): 3.03(t, 4H), 3.32(m, 8H), 3.42(t, 4H), 6.62(d, 2H), 7.52(d, 2H), 7.66(d, 2H), 8.30(d, 2H): EI-MS m/z 450 (M+H).

Example 5

15

4-Bromophenylsulphonyl chloride (1.02 g) was added to a mixture of 1-[1-(3-fluoro-4-pyridyl)-piperidin-4-ylcarbonyl]piperazine hydrochloride (1.22 g) and triethylamine (3.70 ml) in dichloromethane (45 ml) at 0°C. The solution was stirred at ambient temperature for 18 hours. The solution was diluted with dichloromethane and
20 washed with water, dried (Na_2SO_4) and evaporated. The residue was purified by chromatography eluting with 2% methanol in dichloromethane. Recrystallisation from ethyl acetate/hexane gave 1-(4-bromophenylsulphonyl)-4-[1-(3-fluoro-4-pyridyl)piperidin-4-ylcarbonyl]piperazine (1.24 g) as a solid.

Found C, 49.80; H, 4.70 and N, 10.90 %. $\text{C}_{21}\text{H}_{24}\text{BrFN}_4\text{O}_3\text{S}$ requires C, 49.80; H, 4.70 and
25 N, 11.00 %. ^1H NMR (CDCl_3): 1.70 (m, 2H), 1.90 (m, 2H), 2.60 (m, 1H), 2.85 (m, 2H), 3.00 (m, 4H), 3.70 (m, 6H), 6.70 (dd, 1H), 7.60 (d, 2H), 7.70 (d, 2H) 8.10 (d, 1H) and 8.20 (d, 1H); m/z 511 (M+1).

The starting material was prepared as follows:

To a solution of N-benzyloxycarbonyl isonipecotic acid (123.64 g) in
30 tetrahydrofuran (300 ml) at 0°C was added a solution of carbonyldiimidazole (68.80 g) in

tetrahydrofuran (500 ml) and dichloromethane (300 ml). The resulting solution was stirred at ambient temperature for 2 hours. This solution was cooled to 0°C and a solution of 1-(tert-butoxycarbonyl)piperazine (87.02 g) in tetrahydrofuran (200 ml) added dropwise over 20 minutes. The suspension obtained was stirred at ambient temperature for 48 hours.

5 Solvent was evaporated. The residue was dissolved in diethyl ether/dichloromethane (1500 ml) and washed with water, 2M aqueous citric acid solution, saturated aqueous sodium bicarbonate solution, dried (Na_2SO_4) and evaporated to give 1-(tert-butoxycarbonyl)-4-[1-benzyloxycarbonylpiperidin-4-ylcarbonyl]piperazine (180.00 g) as a solid.

10 ^1H NMR (CDCl_3): 1.45 (s, 9H), 1.75 (m, 4H), 2.60 (m, 1H), 2.85 (m, 2H), 3.40 (m, 6H), 3.60 (m, 2H), 4.20 (m, 2H), 5.10 (s, 2H), and 7.35 (m, 5H); m/z 432 ($M+1$).

A solution of 1-(tert-butoxycarbonyl)-4-[1-benzyloxycarbonylpiperidin-4-ylcarbonyl]piperazine (41.31 g) in ethanol (1200 ml) was hydrogenated over 10%

15 palladium-on-carbon for 18 hours. The reaction mixture was filtered through celite and solvent evaporated to give, 1-(tert-butoxycarbonyl)-4-(piperidin-4-ylcarbonyl) piperazine (18.95 g) as a solid.

^1H NMR (CDCl_3): 1.45 (s, 9H), 1.70 (m, 4H), 2.60 (m, 2H), 2.80 (m, 1H), 3.50 (m, 10H); m/z 298

20 To a suspension of 3-fluoro-4-iodopyridine (2.23 g), 1-(tert-butoxycarbonyl)-4-(piperidin-4-ylcarbonyl)piperazine (1.49 g) and sodium t-butoxide (1.06 g) in 1,4-dioxan (20 ml) was added tris(dibenzylidene acetone)dipalladium(0) (0.09 g) and tri-*o*-tolylphosphine (0.12 g) and the mixture heated at reflux for 3 hours. The mixture was diluted with diethyl ether and washed with saturated aqueous sodium chloride solution.

25 dried (Na_2SO_4) and evaporated. The residue was purified by chromatography on alumina (N32-63) eluting with 0.4% methanol in dichloromethane to give as a solid, 1-(tert-butoxycarbonyl)-4-[1-(3-fluoro-4-pyridyl)piperidin-4-ylcarbonyl]piperazine (0.70 g).

^1H NMR (CDCl_3): 1.45 (s, 9H), 1.80 (m, 2H), 2.00 (m, 2H), 2.65 (m, 1H), 2.90 (m, 2H), 3.40 (m, 8H), 3.80 (m, 2H), 6.70 (dd, 1H), 8.10 (d, 1H) and 8.20 (d, 1H); m/z 393 ($M+1$).

30 Ethyl acetate (40 ml) saturated with gaseous HCl was added to a solution of 1-(tert-butoxycarbonyl)-4-[1-(3-fluoro-4-pyridyl)piperidin-4-ylcarbonyl]piperazine (2.60 g) in

ethyl acetate (20 ml) and the resulting suspension stirred at ambient temperature for 3 hours. Solvent was evaporated to give 1-[1-(3-fluoro-4-pyridyl)piperidin-4-ylcarbonyl]piperazine hydrochloride (2.45 g) as a solid.

5 Example 6

4-Trifluoromethylphenylsulphonyl chloride (0.97 g) was added to a mixture 1-[1-(3-fluoro-4-pyridyl)piperidin-4-ylcarbonyl]piperazine hydrochloride (1.22 g) and triethylamine (3.70 ml) in dichloromethane (45 ml) at 0°C. The solution was stirred at ambient temperature for 18 hours. The solution was diluted with dichloromethane and
10 washed with water, dried (Na₂SO₄) and evaporated. The residue was purified by chromatography eluting with 2% methanol in dichloromethane. Recrystallisation from ethyl acetate/hexane gave 1-(4-trifluoromethylphenylsulphonyl)-4-[1-(3-fluoro-4-pyridyl)piperidin-4-ylcarbonyl]piperazine (0.99 g) as a solid.

Found C, 52.90; H, 4.80 and N, 11.10 %. C₂₂H₂₄F₄N₄O₃S requires C, 52.80; H, 4.80 and N,
15 11.20 %. ¹HNMR (CDCl₃): 1.70 (m, 2H), 1.90 (m, 2H), 2.60 (m, 1H), 2.85 (m, 2H), 3.00 (m, 4H), 3.70 (m, 6H), 6.70 (dd, 1H), 7.80 (d, 2H), 7.90 (d, 2H) 8.10 (d, 1H) and 8.20 (d, 1H); m/z 501 (M+1).

The starting material was prepared as follows:

To a solution of N-benzyloxycarbonyl isonipecotic acid (123.64 g) in
20 tetrahydrofuran (300 ml) at 0°C was added a solution of carbonyldiimidazole (68.80 g) in tetrahydrofuran (500 ml) and dichloromethane (300 ml). The resulting solution was stirred at ambient temperature for 2 hours. This solution was cooled to 0°C and a solution of 1-(tert-butoxycarbonyl)piperazine (87.02 g) in tetrahydrofuran (200 ml) added dropwise over 20 minutes. The suspension obtained was stirred at ambient temperature for 48 hours.
25 Solvent was evaporated. The residue was dissolved in diethyl ether/dichloromethane (1500 ml) and washed with water, 2M aqueous citric acid solution, saturated aqueous sodium bicarbonate solution, dried (Na₂SO₄) and evaporated to give 1-(tert-butoxycarbonyl)-4-[1-benzyloxycarbonylpiperidin-4-ylcarbonyl]piperazine (180.00 g) as a solid.

30 ¹HNMR (CDCl₃): 1.45 (s, 9H), 1.75 (m, 4H), 2.60 (m, 1H), 2.85 (m, 2H), 3.40 (m, 6H), 3.60 (m, 2H), 4.20 (m, 2H), 5.10 (s, 2H), and 7.35 (m, 5H); m/z 432 (M+1).

A solution of 1-(tert-butoxycarbonyl)-4-[1-benzyloxycarbonylpiperidin-4-ylcarbonyl]piperazine (41.31 g) in ethanol (1200 ml) was hydrogenated over 10% palladium-on-carbon for 18 hours. The reaction mixture was filtered through celite and solvent evaporated to give, 1-(tert-butoxycarbonyl)-4-(piperidin-4-ylcarbonyl) piperazine
5 (18.95 g) as a solid.

¹HNMR (CDCl₃): 1.45 (s, 9H), 1.70 (m, 4H), 2.60 (m, 2H), 2.80 (m, 1H), 3.50 (m, 10H);
m/z 298

To a suspension of 3-fluoro-4-iodopyridine (2.23 g), 1-(tert-butoxycarbonyl)-4-(piperidin-4-ylcarbonyl) piperazine (1.49 g) and sodium t-butoxide (1.06 g) in 1,4-dioxan
10 (20 ml) was added tris(dibenzylidene acetone)dipalladium(0) (0.09 g) and tri-o-tolylphosphine (0.12 g) and the mixture heated at reflux for 3 hours. The mixture was diluted with diethyl ether and washed with saturated aqueous sodium chloride solution, dried (Na₂SO₄) and evaporated. The residue was purified by chromatography on alumina (N32-63) eluting with 0.4% methanol in dichloromethane to give as a solid, 1-(tert-
15 butoxycarbonyl)-4-[1-(3-fluoro-4-pyridyl)piperidin-4-ylcarbonyl]piperazine (0.70 g).
¹HNMR (CDCl₃): 1.45 (s, 9H), 1.80 (m, 2H), 2.00 (m, 2H), 2.65 (m, 1H), 2.90 (m, 2H), 3.40 (m, 8H), 3.80 (m, 2H), 6.70 (dd, 1H), 8.10 (d, 1H) and 8.20 (d, 1H); m/z 393 (M+1).

Ethyl acetate (40 ml) saturated with gaseous HCl was added to a solution of 1-(tert-butoxycarbonyl)-4-[1-(3-fluoro-4-pyridyl)piperidin-4-ylcarbonyl]piperazine (2.60 g) in
20 ethyl acetate (20 ml) and the resulting suspension stirred at ambient temperature for 3 hours. Solvent was evaporated to give 1-[1-(3-fluoro-4-pyridyl)piperidin-4-ylcarbonyl]piperazine hydrochloride (2.45 g) as a solid.

Example 7

25 N-Chlorosuccinimide (3.63g) was added to a stirred solution of 1-(4-trifluoromethylphenylsulphonyl)-4-[1-(4-pyridyl)piperazin-4-ylcarbonyl]piperazine (12.0g) in acetonitrile (380mL) at 20°C. The mixture was stirred for 48 hours and the acetonitrile evaporated. Water (200mL) was added to the mixture and the aqueous phase was extracted with dichloromethane (3 x 200mL). The organic extracts were combined, dried and
30 evaporated. The residue was purified by column chromatography on silica gel, eluting with a mixture of dichloromethane:methanol (97.5:2.5) to give a foam on evaporation.

Trituration with diethyl ether (250mL) gave 1-(4-trifluorophenylsulphonyl)-4-[1-(3-chloro-4-pyridyl)piperazin-4-ylcarbonyl]piperazine as a pale yellow solid (7.32g); mp 159-160°C; microanalysis found: C, 48.6; H, 4.2; N, 13.1% $C_{21}H_{23}N_5ClF_3O_3S$ requires: C, 48.6; H, 4.4; N, 13.5%; NMR: ($CDCl_3$): 3.04(t, 4H), 3.18(t, 4H), 3.40(t, 8H), 6.78(d, 1H), 7.82(d, 2H), 7.90(d, 2H), 8.33(d, 1H), 8.42(s, 1H); EI-MS m/z 518 (M+H).

The starting material was prepared as follows:

A solution of 4-trifluoromethylphenylsulphonyl chloride (6.62g) in dichloromethane (50mL) was added dropwise over 10 minutes to a stirred solution of 1-[1-(4-pyridyl)piperazin-4-ylcarbonyl]piperazine (5.7g) (prepared as in Example 1) in dichloromethane (50mL) containing triethylamine (6mL) at 20°C. The reaction mixture was stirred for 2 hours at 20°C. The organic phase was washed with water (3 x 100mL) and saturated brine solution (2 x 100mL) dried and evaporated. The residue was purified by chromatography on silica gel, eluting with a mixture of dichloromethane: methanol (95:5) to give, as a sandy-coloured solid, 1-(4-trifluoromethylphenylsulphonyl)-4-[1-(4-pyridyl)piperazin-4-ylcarbonyl]piperazine (6.0g): NMR ($CDCl_3$): 3.08(t, 4H), 3.30-3.40(m, 8H), 3.40-3.45(t, 4H), 6.63(d, 2H), 7.82(d, 2H), 7.90(d, 2H), 8.30(d, 2H); EI-MS m/z 484(M+H).

Example 8

N-Chlorosuccinimide (4.05g) was added to a stirred suspension of 1-(4-fluorophenylsulphonyl)-4-[1-(4-pyridyl)piperazin-4-ylcarbonyl]piperazine (12.45g) in acetonitrile (500mL) at 20°C. The mixture was stirred for 48 hours and the acetonitrile evaporated. Water (200mL) was added to the residue and the aqueous phase extracted with dichloromethane (3 x 200mL). The organic extracts were dried and evaporated. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol (97:3) to give a foam on evaporation. Trituration with diethyl ether (250mL) gave 1-(4-fluorophenylsulphonyl)-4-[1-(3-chloro-4-pyridyl)piperazin-4-ylcarbonyl]piperazine as a pale yellow solid (9.18g): mp 143-144°C: NMR ($CDCl_3$): 3.04(t, 4H), 3.15(t, 4H), 3.41(t, 8H), 6.78(d, 1H), 7.21(d, 2H), 7.78(m, 2H), 8.33(d, 1H), 8.42(s, 1H); EI-MS m/z 468(M+H).

The starting material was prepared as follows:

A solution of 4-fluorophenylsulphonyl chloride (7.8g) in dichloromethane (100mL) was added to a stirred solution of 1-[1-(4-pyridyl)piperazin-4-ylcarbonyl]piperazine (11.0g) (prepared as in Example 1) in dichloromethane (100mL) containing triethylamine (12mL) at 20°C. The mixture was stirred for 2 hours at 20°C. The organic phase was washed with water (3 x 100mL) and saturated brine solution (2 x 100mL), dried, filtered and evaporated. The residue was purified by column chromatography on silica gel, eluting with dichloromethane:methanol (97:3) to give as a salmon-coloured solid, 1-(4-fluorophenylsulphonyl-4-[1-(4-pyridyl)piperazin-4-ylcarbonyl]piperazine (12.45g): NMR (CDCl₃): 3.04(t, 4H), 3.39(m, 12H), 6.63(d, 2H), 7.23(m, 2H), 7.77(m, 2H), 8.30(d, 2H); EI-MS m/z 434 (M+H).

Example 9

Phenylsulphonyl chloride (0.38g) was added to a mixture of 1-[1-(3-fluoro-4-pyridyl)piperazin-4-ylcarbonyl]piperazine dihydrochloride (0.65g) and triethylamine (1.5ml) in dichloromethane (30ml) at 5°C. The solution was stirred at 5°C for 1 hour and at ambient temperature for 18 hours. The solution was evaporated to dryness. The residue was dissolved in dichloromethane (100ml), and the solution was washed with water (3x10ml), dried (Na₂SO₄) and evaporated. The residue was purified by chromatography on alumina (N32-63) using 0.1-0.3% methanol in dichloromethane as eluent. Recrystallisation from ethyl acetate/isohexane gave 1-phenylsulphonyl-4-[1-(3-fluoro-4-pyridyl)piperazin-4-ylcarbonyl]piperazine (0.49g), as an off-white solid mp 143-145°C: NMR (CDCl₃): 3.05 (t, 4H), 3.25 (t, 4H), 3.40 (m, 8H), 6.70 (dd, 1H), 7.60 (m, 3H), 7.78 (s, 2H), 8.20 (dd, 2H); m/z 434 (M+1).

The starting material was prepared as follows:

A solution of 3-fluoropyridine (19.4g) in dry tetrahydrofuran (20ml) was added dropwise over 30 minutes, under an atmosphere of argon, to a stirred solution of 2M lithium diisopropylamide/tetrahydrofuran/heptane (100ml) in dry tetrahydrofuran (700ml) at -70°C. The mixture was stirred at -70°C for 4 hours. A solution of iodine (50.7g) in dry tetrahydrofuran (160ml) was added dropwise to this stirred suspension at -70°C over 45

minutes and stirring was continued for a further 45 minutes. A mixture of tetrahydrofuran (160ml)/water (40ml) was added to the resulting solution at -70°C. The solution was allowed to warm to 0°C. Water (200ml) was added and diethyl ether (400ml). The mixture was allowed to stand at ambient temperature for 16 hours. The ether layer was
5 separated. The aqueous layer was extracted with ether (2x100ml). The ether layers were all combined, washed with aqueous sodium thiosulphate solution (2x250ml) and saturated brine (2x100ml), dried (Na_2SO_4) and evaporated to low bulk. The residue was dissolved in dry diethyl ether and the solution was cooled to -50°C. The solid, which had separated, was filtered off and washed with pentane at -50°C to give 3-fluoro-4-iodopyridine (22.8g)
10 as a white solid: NMR (CDCl_3): 7.75 (t, 1H), 8.05 (d, 1H), 8.35 (s, 1H); m/z 223 M.

Tris(dibenzylideneacetone)dipalladium(0) (0.184g) and tri-*o*-tolylphosphine (0.244g) were added to a suspension of 3-fluoro-4-iodopyridine (4.46g), 1-[1-(*t*-butoxycarbonyl)piperazin-4-ylcarbonyl]piperazine (3.0g) and sodium *t*-butoxide (2.12g) in
15 dry 1,4-dioxane (40ml) under an atmosphere of argon. The mixture was heated at 100°C for 18 hours. The mixture was cooled, diluted with diethyl ether (200ml) and washed with saturated brine (40ml). The aqueous layer was back-extracted with diethyl ether (2x100ml). The ether layers were all combined, washed with saturated brine (2x10ml), dried (Na_2SO_4) and evaporated. The residual oil was purified by chromatography on
20 alumina (N32-63) using 0.1-0.4% methanol in dichloromethane as eluent to give 1-(*t*-butoxycarbonyl)-4-[1-(3-fluoro-4-pyridyl)piperazin-4-ylcarbonyl]piperazine (1.7g) as an orange solid: NMR (CDCl_3): 1.47 (s, 9H), 3.25 (m, 8H), 3.45 (m, 8H), 6.75 (dd, 1H), 8.20 (dd, 2H); m/z 394 (M+1).

25 Ethyl acetate saturated with gaseous HCl (35ml) was added to a solution of 1-(*t*-butoxycarbonyl)-4-[1-(3-fluoro-4-pyridyl)piperazin-4-ylcarbonyl]piperazine (1.6g) in ethyl acetate (16ml). The resulting suspension was stirred vigorously at ambient temperature for 3 hours. The solvent was evaporated to give 1-[1-(3-fluoro-4-pyridyl)piperazin-4-ylcarbonyl]piperazine dihydrochloride (0.65g) as a cream solid.

Example 10

Illustrative pharmaceutical dosage forms suitable for presenting the compounds of the invention for therapeutic or prophylactic use include the following tablet and capsule formulations, which may be obtained by conventional procedures well known in the art of pharmacy and are suitable for therapeutic or prophylactic use in humans:








(a) <u>Tablet I</u>		<u>mg/tablet</u>
Compound Z*		1.0
Lactose Ph. Eur.		93.25
10 Croscarmellose sodium		4.0
Maize starch paste (5% w/v aqueous paste)		0.75
Magnesium Stearate		1.0
15 (b) <u>Tablet II</u>		<u>mg/tablet</u>
Compound Z*		50
Lactose Ph. Eur.		223.75
Croscarmellose sodium		6.0
Maize starch		15.0
20 Polyvinylpyrrolidone (5% w/v aqueous paste)		2.25
Magnesium stearate		3.0
(c) <u>Tablet III</u>		<u>mg/tablet</u>
Compound Z*		100
25 Lactose Ph. Eur.		182.75
Croscarmellose sodium		12.0
Maize starch paste (5% w/v aqueous paste)		2.25
Magnesium stearate		3.0

(d) <u>Capsule</u>	
	<u>mg/capsule</u>
Compound Z*	10
Lactose Ph. Eur.	488.5
5 Magnesium stearate	1.5

Note

- * The active ingredient Compound Z is a compound of formula I, or a salt thereof, for example a compound of formula I described in any of the preceding Examples.
- 10 The tablet compositions (a) - (c) may be enteric coated by conventional means, for example, with cellulose acetate phthalate.


FORMULAE



Claims

1. A compound of formula I, or a pharmaceutically-acceptable salt thereof.

5



wherein:

- 10 R is selected from halogeno, cyano, nitro, carboxy, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkanoyl, (1-6C)alkoxycarbonyl and halogeno(1-6C)alkyl;

R₁ is selected from hydrogen, amino, halogeno, cyano, nitro, carboxy, (1-6C) alkyl, (1-6C)alkoxy, (1-6C)alkanoyl, (1-6C)alkoxycarbonyl, halogeno(1-6C)alkyl, N-(1-6C)alkylamino, N,N-di-[(1-6C)alkyl]amino, (1-6C)alkylthio, (1-6C)alkylsulphinyl and (1-6C)alkylsulphonyl;

- 15 m is 1 or 2;

A is selected from a direct bond and (1-4C)alkylene;

T₁ is selected from N and CR₂, wherein R₂ may be hydrogen, (1-4C)alkyl, (2-4C)alkenyl or (2-4C)alkynyl;

- 20 T₂ is selected from N and CH;

T₃ is selected from N and CR₂, wherein R₂ is as defined above; provided that when T₂ is CH then T₃ is not CR₂ and when T₁ is CR₂ then T₃ is not CR₂;

wherein the heterocyclic ring containing T₁ and the heterocyclic ring containing T₂ may, independently, be optionally substituted by one or more substituents selected from (1-6C)alkyl, (1-6C)alkoxy, phenyl(1-4C)alkyl, halogeno and (1-6C)alkoxycarbonyl;

- 25 Q is selected from a heteroaryl moiety containing up to 3 heteroatoms selected from nitrogen, oxygen and sulphur, phenyl, naphthyl, phenyl(1-6C)alkyl and phenyl(2-6C)alkenyl;

- and wherein Q may be unsubstituted or may bear one or more substituents selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-4C)alkyl, (1-4C)alkylenedioxy, (1-6C)alkylamino, N,N-di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, di-N[(1-6C)alkyl]carbamoyl, (1-6C)alkanoylamino, (1-6C)alkoxycarbonyl, (1-6C)alkylthio, (1-6C)alkylsulphinyl, (1-6C)alkylsulphonyl, halogeno(1-6C)alkyl, (1-6C)alkanoyl and a heteroaryl group comprising a 5- or 6- membered monocyclic heteroaryl ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur.
- 10 2. A compound of formula I, or a pharmaceutically-acceptable salt thereof - according to claim 1 wherein Q is phenyl, naphthyl, or phenyl (2-6C)alkenyl.
3. A compound of formula I, or a pharmaceutically-acceptable salt thereof, according to claim 2 wherein Q is phenyl.
- 15 4. A compound of formula I, or a pharmaceutically-acceptable salt thereof, according to any one of claim 1 to 3, wherein R is selected from halogeno and halogeno(1-6C)alkyl.
5. A compound of formula I or a pharmaceutically-acceptable salt thereof, according to 20 any one of claim 1 to 4, wherein R₁ is selected from hydrogen, amino, (1-6C)alkyl and halogeno.
6. A compound of formula I or a pharmaceutically-acceptable salt thereof according to claim 5 wherein R₁ is hydrogen.
- 25 7. A compound of formula I or a pharmaceutically-acceptable salt thereof according to any one of claims 1 to 6 wherein A is a direct bond.
8. A compound of formula I or a pharmaceutically-acceptable salt thereof according to 30 any one of claims 1 to 7 wherein Q is substituted by at least one substituent selected from

halogeno, (1-6C)alkoxy, (1-6C)alkyl, halogeno(1-6C)alkyl, N,N-di-[(1-4C)alkyl]amino, nitro, cyano, and (1-6C)alkanoylamino.

9. A compound of formula I or a pharmaceutically-acceptable salt thereof selected from:

5 1-(4-trifluoromethylphenylsulphonyl)-4-[1-(3-chloro-4-pyridyl)piperazin-4-ylcarbonyl]piperazine;

1-(4-fluorophenylsulphonyl)-4-[1-(3-chloro-4-pyridyl)piperazin-4-ylcarbonyl]piperazine; and

1-phenylsulphonyl-4-[1-(3-fluoro-4-pyridyl)piperazin-4-ylcarbonyl]piperazine.

10

10. A compound of formula I or a pharmaceutically-acceptable salt thereof according to any claims from 1 to 9 for use in medical therapy.


11. A pharmaceutical composition comprising a compound of formula I or a

15 pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable diluent or carrier thereof.

12. Use of a compound of formula I or a pharmaceutically-acceptable salt thereof, as defined in any one of claims 1 to 9, in the preparation of a medicament for treating diseases or
20 medical conditions in which inhibition of oxido-squalene cyclase is desirable.

13. A method of inhibiting oxido-squalene cyclase in a patient requiring such treatment, which method comprises administering to such animals an effective amount of a compound of formula I or a pharmaceutically-acceptable salt thereof, as defined in any one of claims 1 to 9.
25


14. A process for the preparation of compounds of formula I as defined by claim 1, by:
(a) when T₃ is N, reacting an acid of formula II:



II

wherein R_1 , m , R and T_1 are defined in claim 1, with an amine of formula III, or a reactive derivative thereof

5




III

wherein T_2 and Q are defined in claim 1;


10

(b) when T_2 is N, reacting an amine of formula IV



IV


15 wherein R_1 , m , R , T , A and T_3 are defined in claim 1, with a compound of formula



wherein Z is a displaceable group and Q is as defined in claim 1;

20


(c) when T_1 is N and wherein A is a direct bond, reacting a compound of formula V:



V

wherein R_1 , m and R are as defined in claim 1, with a compound of formula VI or a reactive derivative thereof


5



VIII

wherein T_3 , T_2 and Q are as defined in claim 1;

10 (d) reacting a compound of formula VI



VI

in which Z is a displaceable group and R_1 , m and R are as defined in claim 1, with an amine
15 of formula VII

(e) when R is halogeno, halogenating the corresponding compound of formula I wherein R is hydrogen.

20

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/04 " C07D401/12 C07D213/74 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 10022 A (ZENECA LTD ; FAULL ALAN WELLINGTON (GB); MAYO COLETTE MARIE (GB); P) 4 April 1996 cited in the application see the whole document	1-14
X,P	WO 97 06802 A (ZENECA LTD ; BROWN GEORGE ROBERT (GB); STOKES ELAINE SOPHIE ELISABE) 27 February 1997 see the whole document	1-14

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

25 May 1998

Date of mailing of the international search report

02.06.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-2016

Authorized officer

Bosma, P

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 98/00405

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 13
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9610022	A	04-04-1996	AU 3530795 A	19-04-1996
			CA 2197471 A	04-04-1996
			CZ 9700893 A	16-07-1997
			EP 0783500 A	16-07-1997
			NO 971415 A	22-05-1997
			PL 319430 A	04-08-1997
			SK 38597 A	10-09-1997
			ZA 9508085 A	24-04-1996
WO 9706802	A	27-02-1997	AU 6748596 A	12-03-1997

THIS PAGE BLANK (USPTO)